Arvinas (ARVN) Net Equity Issued and Repurchased (2018 - 2020)
Arvinas (ARVN) posted quarterly Net Equity Issued and Repurchased of $33.3 million for Q4 2020, up 11.25% quarter-over-quarter from $29.9 million in Q3 2020.
Powered by 
Analysis
Arvinas (ARVN) Net Equity Issued and Repurchased (2018 - 2020) Analysis & Trends
Arvinas' Net Equity Issued and Repurchased history runs 2 years deep, the most recent figure standing at $33.3 million for Q4 2020.
- In Q4 2020, Net Equity Issued and Repurchased changed N/A year-over-year to $33.3 million; the TTM figure through Dec 2020 stood at $63.2 million (changed N/A YoY), while the FY2020 annual figure was $64.1 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased for Q4 2020 stood at $33.3 million, up from $29.9 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $55.0 million in Q1 2018, with the low at $29.9 million in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Arvinas | 609.77 Mn | 41.87 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2020 | -30.84 Mn |
| Sep 30, 2020 | 29.90 Mn |
| Mar 31, 2018 | 55.00 Mn |